Evidence map›Paper›PMID 39804435›Full record

ReviewJournal of gastrointestinal cancer2025

Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review.

Rodrigo Gomes Taboada, Maria Fernanda Arruda Almeida, Karina Miranda Santiago, Dirce Maria Carraro, Warley Abreu Nunes, Alessandro Landskron Diniz, Tiago Cordeiro Felismino, Victor Hugo Fonseca de Jesus

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rodrigo Gomes TaboadaDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Maria Fernanda Arruda AlmeidaDepartment of Radiology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Karina Miranda SantiagoDepartment of Clinical and Functional Genomics, International Research Center, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Dirce Maria CarraroDepartment of Clinical and Functional Genomics, International Research Center, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Warley Abreu NunesDepartment of Pathology, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Alessandro Landskron DinizDepartment of Abdominal Surgical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Tiago Cordeiro FelisminoDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Victor Hugo Fonseca de JesusDepartment of Gastrointestinal Medical Oncology, Oncoclínicas, Florianópolis, SC, Brazil. victor.jesus@cepon.org.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor response to chemotherapy. High-frequency microsatellite instability (MSI-H) is a rare biological phenomenon in conventional PDAC, being more frequently described in tumors with medullary or mucinous features. METHODS AND

resultsIn this manuscript, we report the case of a patient with an MSI-H pancreatic carcinoma with medullary features (medullary carcinoma of the pancreas-MCP) that achieved a complete pathological response after neoadjuvant modified FOLFIRINOX. Additionally, we summarize the available evidence on the clinical, pathological, and molecular features of patients with MCP, along with survival outcomes.

conclusionsMCPs present significant sensitivity not only to immune checkpoint inhibitors, but also to systemic chemotherapy and that the latter treatment modality should not be overlooked. They also present different pathological and molecular features compared with conventional PDAC, meaning they should be considered a separate pathological entity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, MedullaryCarcinoma, Pancreatic DuctalPancreatic NeoplasmsFluorouracilHumansIrinotecanLeucovorinMicrosatellite InstabilityNeoadjuvant TherapyOxaliplatinFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinCompleteFOLFIRINOXMedullarNeoadjuvantPancreaticResponse

Identifiers

PMID39804435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.